Assessing quality of life in Alzheimer's disease: Implications for clinical trials

Kristin Kahle-Wrobleski, Wenyu Ye, David Henley, Ann Marie Hake, Eric Siemers, Yun Fei Chen, Hong Liu-Seifert

Research output: Contribution to journalArticle

12 Scopus citations


Introduction Characterization of the quality of life (QOL) in Alzheimer's disease (AD) scale within the context of a clinical trial may inform its applicability in future trials. Methods Using data from 1322 patients enrolled in two phase-III studies (EXPEDITION 1 [NCT00905372] and 2 [NCT00904683]) of intravenous solanezumab in outpatients with mild AD dementia, correlations between patient- and caregiver-assessed QOL and between QOL and clinical outcome measures were examined. Longitudinal effects of solanezumab over 80 weeks were explored, controlling for patient and caregiver baseline characteristics. Results Caregivers rated patients' QOL worse than did patients themselves. Patients' QOL was correlated, albeit modestly, with clinical/health measures. Patients' QOL changed minimally over 80 weeks, although a treatment effect of solanezumab on QOL was detected. Discussion Further investigations are needed to determine the optimal measures with which to quantify and qualify QOL of patients with mild AD.

Original languageEnglish (US)
Pages (from-to)82-90
Number of pages9
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
StatePublished - 2017


  • Alzheimer's disease
  • Caregiver-assessed
  • Clinical trial
  • Patient-assessed
  • Quality of life
  • Solanezumab

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Assessing quality of life in Alzheimer's disease: Implications for clinical trials'. Together they form a unique fingerprint.

  • Cite this